Albert David Limited

NSE ALBERTDAVD.NS

Albert David Limited EPS (Diluted) for the year ending March 31, 2024: USD 1.58

Albert David Limited EPS (Diluted) is USD 1.58 for the year ending March 31, 2024, a 105.42% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Albert David Limited EPS (Diluted) for the year ending March 31, 2023 was USD 0.77, a -5.21% change year over year.
  • Albert David Limited EPS (Diluted) for the year ending March 31, 2022 was USD 0.81, a 53.55% change year over year.
  • Albert David Limited EPS (Diluted) for the year ending March 31, 2021 was USD 0.53, a 18.88% change year over year.
  • Albert David Limited EPS (Diluted) for the year ending March 31, 2020 was USD 0.45, a -33.64% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
Loading...
SV Wall Street
NSE: ALBERTDAVD.NS

Albert David Limited

CEO Mr. Umesh Manohar Kunte
IPO Date June 14, 2016
Location India
Headquarters Gillander House
Employees 1,497
Sector Consumers Staples
Industries
Description

Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, bulk drugs, and disposable syringes and needles in India. It offers formulations for parenterals, oral/enteral, topical agents, and vision care products. The company also exports its products to Latin American, Southeast Asian, and other African countries. The company was incorporated in 1938 and is headquartered in Kolkata, India.

Similar companies

ALEMBICLTD.NS

Alembic Limited

USD 1.33

2.50%

RPGLIFE.NS

RPG Life Sciences Limited

USD 28.88

1.88%

AMRUTANJAN.NS

Amrutanjan Health Care Limited

USD 7.69

0.17%

LINCOLN.NS

Lincoln Pharmaceuticals Limited

USD 8.70

8.00%

HESTERBIO.NS

Hester Biosciences Limited

USD 21.80

0.20%

StockViz Staff

February 8, 2025

Any question? Send us an email